GlassScriptPhysician profile
Sherry Leroy
NPI 1548869142
$3,462.41
in general payments reported to CMS, 2019-2025
40 companies · $777 in 2025
The $777 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $278 · 2022: $670 · 2023: $1,187 · 2024: $551 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,161 · Education: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,160.51 |
| Education | $353.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $372.04 | 2021-2025 | Xtandi, Padcev |
| Janssen Biotech, INC. | $309.00 | 2021-2025 | Erleada, Darzalex, Tecvayli |
| Novartis Pharmaceuticals Corporation | $302.16 | 2023-2025 | |
| Amgen INC. | $289.31 | 2021-2023 | Kyprolis, Nplate, Xgeva |
| Abbvie INC. | $219.70 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $196.72 | 2024-2025 | Opdivo, Krazati |
| Astrazeneca Pharmaceuticals LP | $156.27 | 2021-2025 | Calquence, Enhertu, Lynparza |
| Seagen INC. | $142.52 | 2021-2023 | Adcetris |
| Eisai INC. | $140.99 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $135.51 | 2021-2025 | Keytruda, Lynparza |
| Kite Pharma, INC. | $114.12 | 2021-2023 | |
| Celgene Corporation | $103.26 | 2022-2024 | Pomalyst, Reblozyl |
| Array Biopharma INC | $97.01 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Mirati Therapeutics, INC. | $95.39 | 2023-2024 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $70.53 | 2024-2025 | Iclusig, Ninlaro |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Leroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.